Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pharmacognocist spends time with CRN

This article was originally published in The Tan Sheet

Executive Summary

Dr. Robert Krueger, professor of pharmacognosy at Ferris State (Michigan) University's College of Pharmacy, will work with the Council for Responsible Nutrition during his sabbatical from mid-August through mid-December, the trade group states Aug. 20. Kruger's proficiency in pharmacognosy, "the chemistry and biology of natural products often used in making dietary supplements," will aid CRN to further the science, education and understanding botanical, herbal and other natural products, the association says. He also will join CRN's scientific team in providing counsel and expert advice for member companies, CRN says. In the meantime, the trade group is seeking a botanical expert to join CRN as a full-time, permanent scientist to replace Dr. Robert Borris, who joined the staff of the University of Hawaii's School of Pharmacy as the associate dean of research...

You may also be interested in...

Amgen/AstraZeneca’s Tezepelumab Cuts Asthma Exacerbations By 56%

Data presented at AAAI meeting show reduced annualized asthma exacerbation rates across all patient populations, but doctors are unlikely to switch patients served well by existing biologics. 

Sarepta’s Next-Generation Drugs Draw Attention Amid ‘Incremental’ Approval

The RNA drug’s accelerated approval brings Sarepta’s exon-skipping market share to nearly 30%.

COVID-19 Will Forever Change Workplace, But Not Necessarily For The Better, Merck’s Frazier Says

Limiting interactions to two-dimensional settings will hinder collaboration, innovation and the mentoring of younger employees, Merck & Co. CEO Kenneth Frazier says. Frazier, who will retire in June, is looking forward to returning to public service but says "politics with a capital P is not my thing."





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts